NTRK Fusions

from Springer Nature · host Springer Nature

Identification of molecular alterations in NTRK 1-3 has become increasingly important with the emergence of histology-agnostic, US Food and Drug Administration-approved, effective inhibitors. The host discusses with Dr. Jaclyn Hechtman, director of clinical diagnostic development at Neogenomics, her practical insights on how testing for NTRK fusion can best be implemented and communicated within the multidisciplinary healthcare team.

Episode metadata supplied by the publisher feed · Published Dec 7, 2021

Embed this episode

Attribution link and audio player

NOW PLAYING

NTRK Fusions

0:00 23:00

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Springer Nature?

This episode is 23 minutes long.

When was this Springer Nature episode published?

This episode was published on December 7, 2021.

Can I download this Springer Nature episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!